Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline

Journal of Veterinary Internal Medicine

Volumn 28, Issue 2, 2014, Pages 547-553

  Marconato, L ^a   Zorzan, E ^b   Giantin, M ^b   Di Palma, S ^c   Cancedda, S ^a   Dacasto, M ^b  

^a Clinica Veterinaria dell'Orologio and Centra Oncologico Veterinario   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c IDEXX LABORATORIES   (United States)

Author keywords

Dog; Mastocytoma; Metastasis; Mutation

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ANIMAL; DOG; DOG DISEASE; EXON; FEMALE; GENETIC SCREENING; GENETICS; GENOTYPING TECHNIQUE; MALE; MASTOCYTOMA; MUTATION; PATHOLOGY; SARCOMA; VETERINARY;

ANIMALS; DOG DISEASES; DOGS; EXONS; FEMALE; GENETIC TESTING; GENOTYPING TECHNIQUES; MALE; MAST-CELL SARCOMA; MASTOCYTOMA; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84897766792     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12266     Document Type: Article

References (40)

1. Ma Y, Longley BJ, Wang X, et al. Clustering of activating mutations in c-kit's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 1999;112:165-170.
2. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-697.
3. Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 2008;6:1137-1145.
4. Downing S, Chien MB, Kass PH, et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002;63:1718-1723.
5. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, et al. The role of c-KIT in tumorigenesis: Evaluation in canine cutaneous mast cell tumors. Neoplasia 2006;8:104-111.
6. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, et al. Cellular proliferation in canine cutaneous mast cell tumors: Associations with c-KIT and its role in prognostication. Vet Pathol 2007;44:298-308.
7. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-3865.
8. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1301-1309.
9. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-1043.
10. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-4778.
11. Italiano A, Vandenbos FB, Otto J, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: Implications for treatment with EGFR-inhibitors. Ann Oncol 2006;17:981-985.
12. Brunetti B, Asproni P, Beha G, et al. Molecular phenotype in mammary tumours of queens: Correlation between primary tumour and lymph node metastasis. J Comp Pathol 2013;148:206-213.
13. Beha G, Brunetti B, Asproni P, et al. Molecular portrait-based correlation between primary canine mammary tumor and its lymph node metastasis: Possible prognostic-predictive models and/or stronghold for specific treatments? BMC Vet Res 2012;8:219-227.
14. Amagai Y, Tanaka A, Matsuda A, et al. Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours. J Small Anim Pract 2013;54:377-380.
15. Zavodovskaja R, Chien MB, London CA. Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs. J Vet Intern Med 2004;18:915-917.
16. Gao J, Tian Y, Li J, et al. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. Med Oncol 2013;30:522.
17. Blackwood L, Murphy S, Buracco P, et al. European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol 2012;10:e1-e29.
18. Stefanello D, Valenti P, Faverzani S, et al. Ultrasound-guided cytology of spleen and liver: A prognostic tool in canine cutaneous mast cell tumor. J Vet Intern Med 2009;23:1051-1057.
19. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: Morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
20. Kiupel M, Webster JD, Bailey KL, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 2011;48:147-155.
21. Kobayashi M, Sugisaki O, Ishii N, et al. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. Vet J 2012;193:264-267.
22. Torres-Cabala CA, Wang W-L, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Modern Pathol 2009;22:1446-1456.
23. Giantin M, Vascellari M, Morello EM, et al. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: Correlations with post-surgical prognosis. J Vet Diagn Invest 2012;24:116-126.
24. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
25. White CR, Hohenhaus AE, Kelsey J, Procter-Gray E. Cutaneous MCTs: Associations with spay/neuter status, breed, body size, and phylogenetic cluster. J Am Anim Hosp Assoc 2011;47:210-216.
26. Dobson JM. Breed-predispositions to cancer in pedigree dogs. ISRN Vet Sci 2013;2013:941275.
27. Kiupel M, Webster JD, Miller RA, Kaneene JB. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. J Vet Med A 2005;52:280-286.
28. Murphy S, Sparkes AH, Blunden AS, et al. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec 2006;158:287-291.
29. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001;109:121-124.
30. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the iuxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002;39:529-535.
31. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009;24:106-112.
32. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893-895.
33. Katona TM, Jones TD, Wang M, et al. Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am J Surg Pathol 2007;31:1029-1037.
34. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008;216:64-74.
35. Taniguchi K, Okami J, Kodama K, et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008;99:929-935.
36. Dai B, Cai X, Kong Y-Y, et al. Analysis of KIT expression and gene mutation in human acral melanoma: With a comparison between primary tumors and corresponding metastases/recurrences. Hum Pathol 2013;44:1472-1478.
37. Takeuchi Y, Fujino Y, Watanabe M, et al. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: A retrospective cohort study. Vet J 2013;196:492-498.
38. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-312.
39. Ando K, Oki E, Sugiyama M, et al. Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a case. Surg Today 2011;41:1290-1293.
40. Wang W-L, Hornick JL, Mallipeddi R, et al. Cutaneous and subcutaneous metastases of gastrointestinal stromal tumors: A series of 5 cases with molecular analysis. Am J Dermatopathol 2009;31:297-300.